<div id="readability-page-1"><p>Research analysts at Melius Research assumed coverage on shares of <span>Arxis (NASDAQ:ARXS - Get Free Report)</span> in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a &#34;buy&#34; rating and a $45.00 price target on the stock. Melius Research's price objective suggests a potential upside of 28.21% from the company's current price.</p><p>Several other research firms also recently issued reports on ARXS. Morgan Stanley assumed coverage on shares of Arxis in a report on Monday. They set an &#34;overweight&#34; rating and a $44.00 price objective on the stock. Citigroup assumed coverage on shares of Arxis in a research report on Monday. They issued a &#34;buy&#34; rating and a $42.00 target price on the stock. William Blair assumed coverage on shares of Arxis in a research report on Monday. They issued an &#34;outperform&#34; rating on the stock. The Goldman Sachs Group assumed coverage on shares of Arxis in a research report on Monday. They issued a &#34;buy&#34; rating and a $53.00 target price on the stock. Finally, Rothschild &amp; Co Redburn  set a $40.00 target price on shares of Arxis and gave the company a &#34;buy&#34; rating in a research report on Monday. Ten research analysts have rated the stock with a Buy rating and one  has issued  a Hold rating to the company's stock. According to data from MarketBeat.com, Arxis presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $45.27.</p><p><b>Read Our Latest Analysis on Arxis</b></p><h2>Arxis Stock Performance</h2><p>ARXS opened at $35.10 on Monday. Arxis has a 1 year low of $34.44 and a 1 year high of $39.45. </p><h2>Insider Buying and Selling</h2><p>In related news, Director Stephen Duane Oetgen acquired 25,000 shares of Arxis stock in a transaction that occurred on Friday, April 17th. The shares were purchased at an average price of $28.00 per share, for a total transaction of $700,000.00. Following the completion of the transaction, the director owned 30,357 shares in the company, valued at $849,996. This represents a 466.68% increase in their position. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, insider Ross Bradley Sealfon bought 12,500 shares of the company's stock in a transaction on Friday, April 17th. The stock was bought at an average price of $28.00 per share, with a total value of $350,000.00. Following the completion of the acquisition, the insider owned 1,102,807 shares in the company, valued at $30,878,596. This represents a 1.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 201,564 shares of company stock worth $5,643,792 in the last 90 days. </p><h2>Arxis Company Profile</h2> (Get Free Report)<p>We are a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical components engineered for cutting-edge performance in extreme environments. Leveraging significant intellectual property (“IP”) and world-class engineering capabilities, we design and deliver innovative solutions that address some of our customers' most complex performance needs. Arxis is the result of a deliberate and disciplined strategy executed by our sponsor, Arcline, and the Arxis management team to create a purpose-built, cohesive business through targeted acquisitions with similar product and end market characteristics.</p><h2>See Also</h2><ul><li>Five stocks we like better than Arxis</li><li>The Stars Are Aligning For Apple: Get Ready for $300</li><li>3 Small-Cap Stocks to Buy as the Russell 2000 Extends Its Rally</li><li>Tapestry Stock Drops After Strong Quarter and Raised Outlook</li><li>3 Companies Quietly Essential to Data Center and AI Operations</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJYUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJYUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arxis Right Now?</h2><p>Before you consider Arxis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arxis wasn't on the list.</p><p>While Arxis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARXS

<p>Melius Research has initiated coverage on Arxis (NASDAQ:ARXS), assigning a "buy" rating and a price target of $45.00, indicating a potential upside of 28.21%. Other firms, including Morgan Stanley and Citigroup, have also issued positive ratings. Currently, Arxis has a consensus rating of "Moderate Buy" with a target of $45.27. The stock opened at $35.10, with a 1-year range of $34.44 to $39.45. Recent insider purchases have increased their holdings significantly, reflecting confidence in the company's prospects.</p>

Market Beat

Arxis

Morgan Stanley

Citigroup

Goldman Sachs

Apple

Tapestry

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Arxis (NASDAQ:ARXS) Now Covered by Analysts at Melius Research